Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Ophthalmology
•
Uveitis and Ocular Immunology
How do you manage checkpoint inhibitor-associated Vogt-Koyanagi-Harada (VKH) disease in patients who have poorly controlled diabetes?
Related Questions
How would you approach management of nodular scleritis in the setting of suspected GCA?
How do you approach a patient with idiopathic anterior uveitis who has ongoing disease despite adalimumab every two weeks?
How do you manage Cancer-Associated Retinopathy (CAR) in a patient who doesn’t have a known cancer diagnosis, given the difficulty in finding the underlying cancer and the risks of using immunosuppressive treatments to preserve vision?
How do you decide between steroids alone versus corticosteroids plus csDMARD for non-anterior sarcoid uveitis?
When would you consider discontinuing immunosuppressive treatment in a quiescent uveitis patient without systemic manifestations of inflammation?
How do you differentiate between ocular involvement due to active tuberculosis versus latent infection in a patient with uveitis and suspected tuberculosis?
How do you approach the management of bilateral non-infectious uveitis in the pediatric population?
How do you manage cystoid macular edema (CME) in patients with steroid-induced intraocular hypertension that is resistant to topical treatments?
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
How do you treat idiopathic acute anterior uveitis that recurs immediately after a course of topical corticosteroids?
